190 | Chapter 7 90. Balkhi MY, Willette-Brown J, Zhu F, et al. IKKα-mediated signaling circuitry regulates early B lymphopoiesis during hematopoiesis. Blood. 2012;119(23):5467-5477. doi:10.1182/blood-2012-01-401547 91. Guo F, Tänzer S, Busslinger M, Weih F. Lack of nuclear factor-kappa B2/p100 causes a RelB-dependent block in early B lymphopoiesis. Blood. 2008;112(3):551-559. doi:10.1182/blood-2007-11-125930 92. Sasaki Y, Derudder E, Hobeika E, et al. Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity. 2006;24(6):729739. doi:10.1016/j.immuni.2006.04.005 93. Xie P, Stunz LL, Larison KD, Yang B, Bishop GA. Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity. 2007;27(2):253-267. doi:10.1016/j. immuni.2007.07.012 94. Scherer DC, Brockman JA, Bendall HH, Zhang GM, Ballard DW, Oltz EM. Corepression of RelA and c-rel inhibits immunoglobulin kappa gene transcription and rearrangement in precursor B lymphocytes. Immunity. 1996;5(6):563-574. doi:10.1016/ s1074-7613(00)80271-x 95. Verkoczy L, Aït-Azzouzene D, Skog P, et al. A role for nuclear factor kappa B/rel transcription factors in the regulation of the recombinase activator genes. Immunity. 2005;22(4):519-531. doi:10.1016/j. immuni.2005.03.006 96. Ramsden DA, Nussenzweig A. Mechanisms driving chromosomal translocations: lost in time and space. Oncogene. 2021;40(25):4263-4270. doi:10.1038/s41388021-01856-9 97. Yu W, Lescale C, Babin L, et al. Repair of G1 induced DNA double-strand breaks in S-G2/M by alternative NHEJ. Nat Commun. 2020;11(1):5239. doi:10.1038/s41467-02019060-w 98. Libri A, Marton T, Deriano L. The (Lack of) DNA Double-Strand Break Repair Pathway Choice During V(D)J Recombination. Front Genet. 2021;12:823943. doi:10.3389/ fgene.2021.823943 99. Lu Y, Wu Y, Feng X, et al. CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis. J Clin Invest. 2014;124(4):1672-1684. doi:10.1172/JCI63139 100. Li J, Joo SH, Tsai MD. An NF-kappaB-specific inhibitor, IkappaBalpha, binds to and inhibits cyclin-dependent kinase 4. Biochemistry. 2003;42(46):13476-13483. doi:10.1021/ bi035390r 101. Bride KL, Hu H, Tikhonova A, et al. Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia. Haematologica. 2022;107(8):1746-1757. doi:10.3324/ haematol.2021.279410 102. Oki Y, Fanale M, Romaguera J, et al. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol. 2015;171(4):463-470. doi:10.1111/bjh.13603 103. Verzella D, Cornice J, Arboretto P, et al. The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target. Biomedicines. 2022;10(9). doi:10.3390/biomedicines10092233 104. Rao DS, O’Connell RM, Chaudhuri AA, Garcia-Flores Y, Geiger TL, Baltimore D. MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity. 2010;33(1):48-59. doi:10.1016/j. immuni.2010.06.013 105. Cerna K, Oppelt J, Chochola V, et al. MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells. Leukemia. 2019;33(2):403-414. doi:10.1038/s41375-018-0230-x 106. Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019;26(2):199-212. doi:10.1038/ s41418-018-0246-9
RkJQdWJsaXNoZXIy MTk4NDMw